Insight Molecular Diagnostics Inc.
NASDAQ:IMDX · NASDAQ Capital Market
+$0.18 today
Vol 0.27M · Avg 0.37M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:IMDX · Revenue to Net Income
Key Ratios
Analysis
$1.9M of revenue converted into -$47.8M of net income for the selected period. Gross margin is -431.9% and net margin is -5369.2%, showing how much revenue survives after costs and taxes. EPS is $-1.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M +115.6% | $1.9M +25.1% | $1.5M +56.9% | $958.0K -56.4% | $2.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.9M +238.7% | $1.1M +4.7% | $1.1M +11.7% | $976.0K +25.4% | $778.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $190.0K -74.3% | $740.0K +79.2% | $413.0K +2394.4% | -$18.0K -101.3% | $1.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 4.7% -34.7pp | 39.3% +11.9pp | 27.5% +29.4pp | -1.9% -66.5pp | 64.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $15.9M +61.6% | $9.8M +5.9% | $9.3M +27.3% | $7.3M +45.0% | $5.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.0M +23.1% | $13.8M +3.8% | $13.3M -38.3% | $21.5M +5.6% | $20.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $30.8M -50.2% | $61.8M +141.8% | $25.5M +42.1% | $18.0M -67.4% | $55.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.2M +40.5% | $1.6M -6.9% | $1.7M -67.8% | $5.2M +24.1% | $4.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$47.9M +18.8% | -$59.0M -155.2% | -$23.1M -73.7% | -$13.3M +72.5% | -$48.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1181.7% +1955.8pp | -3137.4% -1599.0pp | -1538.5% -149.2pp | -1389.2% +815.3pp | -2204.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$30.6M +49.9% | -$61.0M -142.8% | -$25.1M -39.7% | -$18.0M +66.5% | -$53.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -754.1% +2491.1pp | -3245.1% -1572.7pp | -1672.4% +206.2pp | -1878.6% +565.7pp | -2444.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $109.0K +29.8% | $84.0K +61.5% | $52.0K -37.3% | $83.0K -60.3% | $209.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$19.6M -5296.8% | $378.0K +34.5% | $281.0K +145.7% | -$615.0K -172.0% | $854.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$50.2M +17.2% | -$60.7M -144.1% | -$24.9M -33.5% | -$18.6M +64.8% | -$52.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1238.5% +1986.5pp | -3225.0% -1571.3pp | -1653.7% +289.1pp | -1942.8% +462.6pp | -2405.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 +100.0% | -$9.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$50.2M +17.2% | -$60.7M -118.4% | -$27.8M +61.9% | -$72.9M -13.7% | -$64.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1238.5% +1986.5pp | -3225.0% -1376.7pp | -1848.4% +5761.4pp | -7609.8% -4693.7pp | -2916.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +64.6% | -$5 -24.3% | -$4 +81.3% | -$20 -38.9% | -$14 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +64.6% | -$5 -24.3% | -$4 +81.3% | -$20 -38.9% | -$14 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $30.5M +133.2% | $13.1M +70.8% | $7.7M +38.1% | $5.5M +24.6% | $4.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $30.5M +133.2% | $13.1M +70.8% | $7.7M +38.1% | $5.5M +24.6% | $4.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$62.14M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IMDX generate?
Insight Molecular Diagnostics Inc. (IMDX) reported $4.05M of revenue in fiscal 2025.
Is IMDX profitable?
Insight Molecular Diagnostics Inc. (IMDX) reported -$50,222,000.00 of net income, with a net margin of -1238.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.